Key Findings
In a groundbreaking proof-of-concept study, five women with autoimmune primary ovarian insufficiency (POI) received immunotherapy to suppress the autoimmune process. Mature eggs were successfully obtained and either frozen or fertilized.
Three of these women went on to have embryos transferred and subsequently gave birth to healthy babies. Embryo transfer was performed at least one year after treatment. One serious side effect was reported, which researchers attributed to hormone stimulation rather than the immunotherapy itself.
Participant Characteristics
All women who responded to treatment had autoimmune Addison's disease, a condition in which the immune system attacks the adrenal glands. This specific trait may be key to understanding which patients could benefit from the approach.
Study Limitations
This was a proof-of-concept study conducted without a control group and involving a small number of participants. As a result, the findings require cautious interpretation and cannot yet be generalized.
Researcher Statement
"This is a first step. To determine whether the method is effective and safe, larger, randomised studies are required."
— Angelica Lindén Hirschberg, professor at Karolinska Institutet and study first author
Next Steps
The research team has already launched a larger, randomized study to further evaluate the method's effectiveness and safety.
Collaboration and Funding
The study was conducted by researchers at Karolinska Institutet, Karolinska University Hospital, and the University of Bergen.
Funding was provided by:
- The Swedish Research Council
- The Knut and Alice Wallenberg Foundation
- The Novo Nordisk Foundation
- Region Stockholm
The researchers report no conflicts of interest.